Spruce Biosciences Announces $50.0 Million Private Placement Financing | Spruce Biosciences
Summary
Spruce Biosciences announced a private placement expected to raise about $50 million before expenses. The company plans to use the proceeds to advance TA-ERT for Sanfilippo Syndrome Type B through a BLA submission in early 2026 and a possible U.S. launch in late 2026. The financing is set to close around October 9, 2025, subject to customary conditions. Investors will receive common stock and some pre-funded warrants as part of the deal. The release also names the placement agents and capital markets advisor involved in the transaction.
Funding
Amount
$50.0M
Total raised
Date
October 8, 2025
Announcement date
Investors
Oppenheimer & Co.
Lead investors
Company
sprucebio.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected